TechFlow, August 21 — According to a U.S. Securities and Exchange Commission (SEC) notice, due to failing to meet the minimum bid price requirement (Rule 5550(a)(2)), Nasdaq will suspend trading of Windtree Therapeutics (WINT), a BNB treasury company, and delist its common stock from the Nasdaq Capital Market at the opening of trading on August 21, 2025.
Windtree Therapeutics stated that its common stock will begin trading on the over-the-counter market (OTC Markets) on the same day under the unchanged ticker symbol "WINT." The company has applied to trade on the OTC Pink Open Market tier, though confirmation has not yet been received. The company emphasized that the move to the OTC market will not affect its business operations, and it will continue filing periodic reports and other required documents with the SEC in accordance with federal securities laws.
Previous reports indicated that Windtree Therapeutics had announced plans to raise up to $520 million through an equity financing, with 99% of the proceeds intended for purchasing BNB. Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company.
